Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy

Journal of the American College of Cardiology

Volumn 35, Issue 6, 2000, Pages 1590-1598

  Felix, Stephan B ^a   Staudt, Alexander ^a   Dörffel, Wolf V ^a   Stangl, Verena ^a   Merkel, Kurt ^b   Pohl, Manfred ^c   Döcke, Wolf D ^d   Morgera, Stanislao ^c   Neumayer, Hans H ^c   Wernecke, Klaus D ^e   Wallukat, Gerd ^f   Stangl, Karl ^a,c   Baumann, Gert ^a  

^a Medizinische Klinik   (Germany)

^b Inst Pathol und Dermatohistologie   (Germany)

^c Inst für Med Biophysik   (Germany)

^d Und   (Germany)

^e HUMBOLDT UNIVERSITY   (Germany)

^f MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CHOLESTEROL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN; HEART ANTIBODY; HEPARIN; IMMUNOGLOBULIN G; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY CD3; OKT 4; POLYCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; VENIMMUN N;

ADULT; ARTICLE; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOSE RESPONSE; HEART DILATATION; HEART HEMODYNAMICS; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART STROKE VOLUME; HUMAN; IMMUNOADSORPTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBSTITUTION THERAPY; SWAN GANZ CATHETER; SYSTEMIC VASCULAR RESISTANCE; THERMODILUTION;

ADULT; AUTOANTIBODIES; CARDIOMYOPATHY, DILATED; HEMODYNAMIC PROCESSES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSORBENT TECHNIQUES; MALE; MIDDLE AGED; MYOCARDIUM; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 17144438151     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00568-4     Document Type: Article

References (30)

1. Richardson P., McKenna W., Bristow M., et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation. 93:1996;841-842.
2. Limas C.J., Goldenberg I.F., Limas C. Soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. Correlation with disease severity and cardiac autoantibodies. Circulation. 91:1995;631-634.
3. Schwimmbeck P.L., Badorff C., Schultheiss H.P., Strauer B.E. Transfer of human myocarditis into severe combined immunodeficiency mice. Circ Res. 75:1994;156-164.
4. Schulze K., Becker B.F., Schauer R., Schultheiss H.P. Antibodies to ADP-ATP carrier - an autoantigen in myocarditis and dilated cardiomyopathy - impair cardiac function. Circulation. 81:1990;959-969.
5. Caforio A.L., Grazzini M., Mann J.M., et al. Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation. 85:1992;1734-1742.
6. Limas C.J., Goldenberg I.F., Limas C. Autoantibodies against beta-adrenoceptors in human idiopathic dilated cardiomyopathy. Circ Res. 64:1989;97-103.
7. Magnusson Y., Wallukat G., Waagstein F., Hjalmarson A., Hoebeke J. Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta 1 adrenoceptor with positive chronotropic effect. Circulation. 89:1994;2760-2767.
8. Fu M.L., Schulze W., Wallukat G., Hjalmarson A., Hoebeke J. A synthetic peptide corresponding to the second extracellular loop of the human M2 acetylcholine receptor induces pharmacological and morphological changes in cardiomyocytes by active immunization after six month in rabbits. Clin Immunol Immunopathol. 78:1996;203-207.
9. Dörffel W.V., Felix S.B., Wallukat G., et al. Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation. 95:1997;1994-1997.
10. Dwyer J. Manipulating the immune system with immune globulin. N Engl J Med. 326:1992;107-116.
11. Godeau B., Lesage S., Divine M., Wirquin V., Farcet J., Bierling P. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood. 82:1993;1415-1421.
12. Snyder H., Cochran S., Balint J., et al. Experience with protein A-immunoadsorption in treatment-resistant adult immune thrombocytopenic purpura. Blood. 79:1992;2237-2245.
13. Arsura E., Bick A., Brunner N., Namba T., Grob D. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med. 146:1986;1365-1368.
14. Grob D., Simpson D., Mitsumoto H., et al. Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology. 45:1995;338-344.
15. Jackson M., Godwin-Austen R., Whiteley A. High-dose intravenous immunoglobulin in the treatment of Guillain-Barre syndrome a preliminary open study . J Neurol. 240:1993;51-53.
16. Tagawa Y., Yuki N., Hirata K. Ability to remove immunoglobulins and anti-ganglioside antibodies by plasma exchange, double-filtration plasmapheresis and immunoadsorption. J Neurol Sci. 157:1998;90-95.
17. McNamara D.M., Rosenblum W.D., Janosko K.M., et al. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation. 95:1997;2476-2478.
18. Kühl U., Noutsias M., Schultheiss H.P. Immunohistochemistry in dilated cardiomyopathy. Eur Heart J. 16:1995;100-106.
19. Wallukat G., Wollenberger A. Effects of serum gamma globulin fraction in patients with allergic asthma and dilated cardiomyopathy on chronotropic beta-adrenoceptor function in cultured neonatal rat heart myocytes. Biomed Biochem Acta. 46:1987;634-639.
20. Jin O., Sole M.J., Butany J.W., McLaughlin P.R., Liu P., Liew C.C. Detection of enterovirus RNA in myocardial biopsies from patients with myocarditis and cardiomyopathy using gene amplification by polymerase chain reaction. Circulation. 82:1990;8-16.
21. Liao L., Sindhwani R., Rojkind M., Factor S., Leinwand L., Diamond B. Antibody-mediated autoimmune myocarditis depends on genetically determined target organ sensitivity. J Exp Med. 181:1995;1123-1131.
22. Matsumori A., Yamada T., Suzuki H., Matoba Y., Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 72:1994;561-566.
23. Torre-Amione G., Kapadia S., Lee J., et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 93:1996;704-711.
24. Ferrari R., Bachetti T., Confortini R., et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation. 92:1995;1479-1486.
25. Torre-Amione G., Kapadia S., Benedict C., Oral H., Young J.B., Mann D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction a report from the studies of left ventricular dysfunction (SOLVD) . J Am Coll Cardiol. 27:1996;1201-1206.
26. Yokoyama T., Vaca L., Rossen R.D., Durante W., Hazarika P., Mann D.L. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest. 92:1993;2303-2312.
27. Milani R.V., Mehra M.R., Endres S., et al. The clinical relevance of circulating tumor necrosis factor-alpha in acute decompensated chronic heart failure without cachexia. Chest. 110:1996;992-995.
28. Müller J., Wallukat G., Wenig Y.-G., et al. Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation. 96:1997;542-549.
29. Matsui S., Fu M.L., Katsuda S., et al. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J Mol Cell Cardiol. 29:1997;641-655.
30. Roifman C., Levison H., Gelfand E. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinemia and chronic lung disease. Lancet. 1:1987;1075-1077.